Humber River Hospital I Clinical Research Office

Research site

Location

1235 Wilson Avenue, Toronto, Ontario, Canada

Site insights

Top conditions

Top treatments

Tamoxifen

Letrozole

LY2835219

Abemaciclib

Obinutuzumab

Capecitabine

Ibrutinib

Sacituzumab

Pemafibrate

Trastuzumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Manager, Research

Verified by this site

Active trials

7 of 49 total trials

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer (MONARCH 2)

The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor...

Active, not recruiting

Breast Neoplasms

Drug: Placebo

Drug: Fulvestrant

A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Enrolling

Breast Neoplasms

Drug: Anastrozole

Drug: Tamoxifen

Clinical Surveillance Tool to Screen for Unmet Palliative Needs Among Patients in the Final Year of Life (HOMR)

One of the most important obstacles to improving end-of-life care is the inability of clinicians to reliably identify those who are approaching the e...

Invitation-only

Implementation Science

Screening

Other: modified Hospital One-year Mortality Risk (mHOMR)

Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

Durvalumab is a new type of drug for many kinds of cancer. It is considered "immunotherapy" and not "chemotherapy". Laboratory tests show that it wor...

Active, not recruiting

Lung Cancer Metastatic

Drug: Platinum-Based Drug

Drug: Durvalumab

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early s...

Active, not recruiting

Breast Cancer

Drug: Standard Adjuvant Endocrine Therapy

Drug: Abemaciclib

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer...

Active, not recruiting

Locally Advanced or Unresectable Metastatic Breast Cancer

Stage IV Breast Cancer

Drug: Paclitaxel

Drug: Capecitabine

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)

This study is an adaptive, randomized, open-label, controlled clinical trial, in collaboration with countries around the world through the World Heal...

Active, not recruiting

COVID-19

Drug: Imatinib

Drug: Artesunate